A post-hoc analysis has indicated that aflibercept 8 mg has the potential to shorten or lengthen intervals between treatment in patients with DME.
Mark Barakat, MD
Advertisement
Mark Barakat, MD
Director of Retinal Research Institute
Retinal Consultants of Arizona
Phoenix, AZ
Articles by Mark Barakat, MD
Mark Barakat, MD, reviews the best practices for patient communication and shared decision making.
Mark Barakat, MD, discusses the phase 3 TENAYA and LUCERNE trials for patients with neovascular age-related macular degeneration (nAMD).
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
FDA Approves Olezarsen (Tryngolza) for Severe Hypertriglyceridemia
2
Delgocitinib Approval Fills a Long-Standing Gap in Chronic Hand Eczema Treatment
3
Q&A: Cardiometabolic Care Cascade Failure Points, with Rishi Wadhera, MD, MPP, MPhil
4
Q&A: CKM Care, IRA Policy, and Specialty Silos, With Rishi Wadhera, MD, MPP, MPhil
5